

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>C07C 231/14, 231/10, 233/43</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 92/05147</b> <b>(43) International Publication Date:</b> 2 April 1992 (02.04.92)
<b>(21) International Application Number:</b> PCT/SE91/00643 <b>(22) International Filing Date:</b> 25 September 1991 (25.09.91)  <b>(30) Priority data:</b> 9003057-8 26 September 1990 (26.09.90) SE  <b>(71) Applicant (for all designated States except US):</b> AKTIEBOLAGET ASTRA [SE/SE]; S-151 85 Södertälje (SE).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> TROFAST, Jan, William [SE/SE]; Vapenkroken 34, S-222 47 Lund (SE). JAKUPOVIC, Edib [YU/SE]; Smultronvägen 7, S-155 00 Nykvarn (SE). MÅNSSON, Lena, Katarina [SE/SE]; Gamla Huddingevägen 449 B, S-123 43 Älvsjö (SE).		<b>(74) Agents:</b> DANIELSSON, Sten et al.; AB Astra, Patent Department, S-151 85 Södertälje (SE).  <b>(81) Designated States:</b> AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE, DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL, NL (European patent), NO, PL, RO, SD, SE, SE (European patent), SN (OAPI patent), SU*, TD (OAPI patent), TG (OAPI patent), US.  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> NEW PROCESS FOR PREPARING FORMOTEROL AND RELATED COMPOUNDS  <b>(57) Abstract</b>  The present invention is directed to a process for preparing formoterol and related compounds and derivatives thereof and their pharmacologically and pharmaceutically acceptable salts and/or solvates. The present invention is also directed to certain formoterol related compounds per se.		

# + DESIGNATIONS OF "SU"

Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

## *FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU+	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

NEW PROCESS FOR PREPARING FORMOTEROL  
AND RELATED COMPOUNDS.

Field of the invention

5       The present invention relates to an improved and simplified process for the preparation of formoterol and related compounds and derivatives thereof and their pharmacologically and pharmaceutically acceptable fumarate salts and/or solvates. The invention is also directed to  
10       new compounds as defined in claim 9. Formoterol is a long-acting and highly selective bronchodilator. The  $\beta_2$ -adrenoceptor agonists taken by inhalation are the administration of choice in the symptomatic therapy of obstructive airway disease.

15       Background of the invention


          The administration by inhalation enables the dose to be delivered directly to the airways. By this route of  
20       administration, it is possible to give a small dose and thereby minimizing unwanted side-effects. The drawbacks of the current available bronchodilators are their relatively short duration of action. Studies with formoterol given by inhalation have shown its much longer duration than any  
25       other bronchodilators on the market. By using a compound with long duration it would be possible to avoid the nocturnal asthma, so often causing considerable anxiety and debility to the patients. Formoterol gives less nocturnal waking. Formoterol has been registered for oral  
30       administration in Japan since 1986.

          Formoterol has two asymmetric carbon atoms in the molecule. It is used as the fumarate salt of one of the two possible pairs of enantiomers of 3-formamido-4-  
35       hydroxy- $\alpha$ -[N[1-methyl-2-(p-methoxyphenyl)ethyl]amino-methyl]benzyl alcohol. Formoterol consists of the enantiomers, which have the RR + SS configuration.

Formoterol was first described in a Japanese patent application (Yamanouchi Pharmaceutical, Japan no 13121, priority 5 february 1972, related priorities Japan no 39416 (19 april 1972), 51013 (23 May 1972) and 52925 (27 May 1972)). The corresponding patent in Germany is DE 2 305 092.

DE 2 366 625 discloses some  $\alpha$ -aminomethylbenzyl alcohol derivatives which are intermediates for preparing end products useful as bronchodilators. Example 3 therein refers to the preparation of 3-formamido-4-hydroxy- $\alpha$ -(N-benzyl-N-isopropylaminomethyl)benzylalcohol.

The hitherto published synthetic routes to formoterol involve a nucleophilic substitution reaction of an amine to a bromoketone according to:



The reduction of the nitrogroup is accomplished by either Fe/HCl or Sn/HCl followed by formylation with a mixture of formic acid and acetic anhydride. The presence of acetic anhydride has shown to give some undesired acetylated products. The separation step of the two pairs of enantiomers are tedious and several recrystallizations are needed to obtain sufficient purity of the product.

The patent application J 50012-040 (priority date 31 May 1973) discloses a process where a substituted ketone is undergoing a reductive alkylation with the appropriate amine.

ES 2 005 492 (S.A. Lasa Laboratorios) describes a process for the synthesis of formoterol characterized by a coupling reaction between 3-formamido-4-benzyloxyphenyloxirane and the unprotected 2-(4-methoxyphenyl)-1-


methylethyl amine and is followed by tedious and troublesome steps (use of crown ethers, hydrofluoric acid, solvents like benzene and methylene chloride causing environmental and health problems, HCOOH/acetic anhydride etc.) to the final product.

The synthesis of formoterol and closely related compounds have also been reported in Chem. Pharm. Bull., 25(6), 1368-1377 (1977), where 3-nitro-4-benzyloxy- $\alpha$ -(N-substituted aminomethyl)benzyl alcohols are used as the key intermediate. Use of Raney-nickel for the reduction of the nitro group has been rejected due to difficulties in obtaining pure products without a chromatographic step. However, the general procedure for the preparation of 3-amino-4-benzyloxy- $\alpha$ -(N-substituted aminomethyl)benzyl alcohols reported on page 1373 of said document involves a tedious and cumbersome column chromatographic step on silica gel using benzene-ethyl acetate as the eluent.

There is a strong desire of synthesizing formoterol fumarate (as dihydrate) by a simple procedure causing small environmental concerns e.g. by elimination of solvents like benzene.

#### Brief description of the invention.

The present invention is directed to a process for preparing a compound of the general formula I




wherein R<sup>1</sup> is H or a straight or branched alkyl group having 1-5 carbon atoms,


A is either  $\begin{array}{c} \text{R} \\ | \\ -\text{N}^+- \\ | \\ \text{R}^2 \end{array}$  wherein R is H or a straight or branched alkyl group having 1-5 carbon atoms and R<sup>2</sup> is H or a straight or branched alkyl group having 1-5 carbon atoms; or  $\begin{array}{c} \text{R} \\ | \\ -\text{N}- \end{array}$  wherein R is as defined above,

or a pharmaceutically acceptable fumarate and/or solvate thereof, in the form of the pure racemates or the mixture of the four isomers, by


a) reacting



to give compound IV



b) reducing and formylating compound IV to give compound V



c) forming the fumarate of compound V and resolving the racemates by crystallization,

d) extracting the base of the desired racemate of compound V,

e) hydrogenolyzing of the protecting benzyl groups of said base of compound V to obtain compound I wherein A is  $\begin{array}{c} \text{H} \\ | \\ -\text{N}- \end{array}$  and  $\text{R}^1$  is H, and optionally

f) forming a fumarate and/or solvate of compound I, and optionally


g) when

A is either  $\begin{array}{c} \text{R} \\ | \\ -\text{N}^+- \\ | \\ \text{R}^2 \end{array}$  wherein R is H or a straight or

branched alkyl group having 1-5 carbon atoms and  $\text{R}^2$  is H or a straight or branched alkyl group having

1-5 carbon atoms; or  $\begin{array}{c} \text{R} \\ | \\ -\text{N}- \end{array}$  wherein R is a straight or branched alkyl group having 1-5 carbon atoms, and  $\text{R}^1$  is as defined above, alkylating the compound obtained in step e) or f).

Another aspect of the present invention refers to a new compound of the general formula I



I

wherein R<sup>1</sup> is H or a straight or branched alkyl group having 1-5 carbon atoms,

A is either  $\begin{array}{c} \text{R} \\ | \\ -\text{N}^+- \\ | \\ \text{R}^2 \end{array}$  wherein R is a straight or


branched alkyl group having 1-5 carbon atoms and R<sup>2</sup> is H or a straight or branched alkyl group having

1-5 carbon atoms; or  $\begin{array}{c} \text{R} \\ | \\ -\text{N}- \end{array}$  wherein R is as defined above,


or a pharmaceutically acceptable fumarate and/or solvate thereof, in the form of the pure racemates or the mixture of the four isomers.

#### Detailed description of the invention


The starting material 4-benzyloxy-3-nitro-styreneoxide (4-benzyloxy-3-nitro-phenyloxirane) (II) is prepared according to the method described in J. Med. Chem. 17, 49 (1974) by C. Kaiser et al.



According to the present invention formoterol, i.e. the compound of formula I wherein R and R<sup>1</sup> are hydrogen, is prepared by a) reacting



in the presence of a solvent such as lower alcohols at reflux temperatures or in the absence of a solvent at temperatures preferably at 80-120°C, to give compound IV



b) reducing and formylating compound IV to give compound V in either a one step reaction with e.g. Raney-nickel/formic acid or in a two step reaction (catalytic reduction of the nitro group, e.g. over platinum metals in a polar solvent, such as lower alcohols and/or esters, preferably  $\text{PtO}_2$  in methanol or more preferably Pt/C in ethyl acetate, to give compound IVa, followed by formylation, e.g. in a 6-10 fold excess of formic acid). The formylation step is preferably performed at a temperature of 20-90°C during 1-24 hrs. The mixture of the two racemates of V (RR + SS and RS + SR resp.) are thereafter separated by

c) transforming the amine base into its fumarate salt for separation by fractional crystallization in a solvent system comprising ethyl acetate, isopropyl acetate and/or

5 methyl isobutylketone. A very efficient system is based upon a solvent system which also comprises small amounts (preferably less than 15 %) of solvents more polar than the solvents just mentioned, such as dimethylformamide (DMF), dimethylsulfoxide (DMSO) and/or methanol. A preferred solvent system comprises ethyl acetate and a small amount of dimethylformamide, dimethylsulfoxide or methanol. The presence of a solvent like DMF is very important in order to increase the solubility and thereby improve the purity of the desired diastereomer.

15 Step e) is a common hydrogenolysis of the protecting benzyl groups of the amine base V, performed in a traditional manner with platinum, palladium, and nickel catalysts in a polar solvent, such as ethanol, isopropanol or ethylacetate or a mixture of said solvents, at normal or higher temperature and pressure. A simple crystallization of the formoterol base by means of isopropanol or preferably by means of a isopropanol/water mixture may be carried out in connection with this step as a work up procedure. Said crystallization should be carried out at a temperature as low as possible (e.g. < 45°C).

25 The formoterol may thereafter in step f) be transformed into its fumarate salt and/or solvate and crystallized in a polar solvent (isopropanol, ethanol and the like) containing some water (2-25%, preferably 20 %) in order to obtain suitable solid state properties of the compound (hydrate) for the micronization procedure. The compounds usually exist as solvates (hydrates) giving the possibility of different crystal arrangements (polymorphism).

35 The solvents may or may not be completely evaporated in each step in the process. It is preferred by technical reasons not to evaporate the solvents.

In case R in formula I is a straight or branched alkyl group having 1-5 carbon atoms, such as methyl, ethyl, propyl, iso-propyl, a further step g) is necessary, wherein the compound obtained in step e) or step f) is alkylated in a conventional manner, such as by nucleophilic substitution with alkyl halides or by reductive alkylation.

R in the definition of compound I is preferably hydrogen or a straight alkyl group of 1 to 3 carbon atoms.

#### Examples

The invention is further illustrated but not limited by the following examples.

#### Test methods

The purity of the synthesized compounds has been determined on a HPLC (high performance liquid chromatography) system with UV detection using a LiChrosphere RP Select B 5  $\mu$ m (125 x 4 mm) column under the following conditions:

##### System A:

Mobile phase : CH<sub>3</sub>CN:phosphate buffer pH 4.95 (55:45)  
Detection wavelength : 280 nm  
Flow rate : 1.0 ml/min  
Retention time (min) : II 4.8; III 1.9; IV 15 (RR,SS) 17 (RS,SR); IVa 6.7; V 5.5

##### System B:

Mobile phase : CH<sub>3</sub>CN:ethanol:phosphate buffer pH 4.95 (24:16:60)  
Detection wavelength : 280 (220) nm  
Flow rate : 1.0 ml/min  
Retention time (min) : V 40 (RR,SS) 48 (RS,SR)

System C:

Mobile phase : CH<sub>3</sub>CN:ethanol: 0.1 M NH<sub>4</sub>OAc in 0.1  
M HOAc (11:11:78)  
5 Detection wavelength : 280 nm  
Flow rate : 0.8 ml/min  
Retention time (min) : I 8.7

10 The reactions have continuously been followed by HPLC and  
the given data for yield, purity are taken directly from  
the chromatogram unless otherwise stated.

PreparationSynthesis of IV. (step a)

15 4-Benzyloxy-3-nitro-styrenoxide (II, 0.5 mole, 135.8 g)  
and p-methoxyphenyl-2-benzylaminopropane (III, 0.55 mole,  
140.5 g) were stirred under nitrogen atmosphere at 90°C  
for 69 hours (no solvent). The dark syrup (267.0 g)  
20 consisted of 94 % of compound IV with a diastereomer ratio  
of 43:57 (System A).

Synthesis of V. (step b)

25 Method A (two steps). The dark syrup (IV, 133.5 g) in  
methanol (1.5 l) was hydrogenated over 1.5 g PtO<sub>2</sub> xH<sub>2</sub>O at  
a pressure of 2-4 bar for 3 hours. Compound IVa with a  
purity of 91 % was obtained (System A).  
Filtration and evaporation of the solvent followed by  
30 addition of a seven fold excess of formic acid gave after  
standing for 24 hours at 20°C compound V with a purity of  
87 % V (System A) after evaporation. The reaction mixture  
was used without further purification.

An alternative of Synthesis of IV and V

35 4-Benzyloxy-3-nitro-styreneoxide(II, 164 mole, 44.5 kg)  
and p-methoxyphenyl-2-benzylaminopropane (III, 179 mole,

45.8 kg) were stirred under nitrogen atmosphere at 90°C for 65 hours (no solvent). To the dark syrup dissolved in ethyl acetate (350 l) was added Pt/C (5.6 kg).

5 Hydrogenation with hydrogen gas gave after evaporation of the solvent an oily solid of V with 91.3 % purity. The product was used without further purification.

Method B (one step)

10

The dark syrup (IV, 5.0 g), Raney nickel (5 g) and 75 % (v/v) aqueous formic acid (50 ml) were refluxed for 1 hr. The mixture was filtered, and the filtrate and washings diluted with water and extracted with chloroform. The  
15 extracts were washed with saturated sodium hydrogen carbonate, water and dried ( $\text{Na}_2\text{SO}_4$ ). The oily residue was chromatographed on a silica column using petroleum ether (40-60° C)/ethyl acetate (7.5:6) as eluent giving pure compound V (1.8 g).

20

Separation of the diastereomers (step c)

To fumaric acid (0.62 mole, 72.5 g) dissolved in methanol (2 l) the reaction mixture consisting of compound V (about  
25 1.25 mole) in formic acid was added. After evaporation of the solvents at 50°C the brown syrup was dissolved in ethyl acetate (7.5 l) while heating. The light brown crystals of compound V fumarate formed during cooling were filtered, washed with ethyl acetate (1 l) and dried in  
30 vacuum at 40°C for 20 hours. The product (1.12 mole, 654.7 g) had a diastereomer ratio of 84:16 (System B).

1.10 mole (644.7 g) of compound V fumarate in ethyl acetate (7.5 l) was heated to reflux, DMF (750 ml) was added and the clear solution was allowed to stand for 4  
35 days at room temperature. The light brown crystals formed, were washed with ethyl acetate (1.5 l) and dried in vacuum at 40°C for 4 hours giving a diastereomer ratio of 98.5:1.5. By repeating the recrystallization procedure, a

racemic purity of compound V of almost 100 % was obtained in good yield (System B).

Synthesis of I.

5     Step d

The protected (N,O-dibenzylated) formoterol base (V) was obtained by an extraction procedure (ethyl acetate (2 l)/ammonia, 2 M (1.5 l)) from compound V fumarate (0.28 mole, 164.1 g).

10    Step e

Hydrogenolysis of compound V (0.28 mole) in ethanol (2.5 l) with 5 % Pd/C (16.0 g) at 45 psi over night gave the formoterol base (0.23 mole, 78 g (82 %); purity 99.2 %) after filtration and evaporation of the solvent.

15    Recrystallization in isopropanol (1.1 l) increased the purity to 99.8 %. An alternative procedure for recrystallization giving even better purity (>99.9 %) involves the use of a mixture of isopropanol/water (e.g. 85:15) and keeping the temperature as low as possible (e.g. <45°C).

20    Step f

To formoterol base (0.176 mole, 60.6 g) in isopropanol (960 ml) and water (200 ml) fumaric acid (0.088 mole, 10.21 g) was added. A clear solution was obtained after heating. After standing at room temperature the crystals were filtered, washed with isopropanol (2 x 50 ml) and dried in vacuum at 45°C for two days. The formoterol fumarate dihydrate formed (0.17 mole, 69.7 g) had a purity of 99.2 % and an diastereomeric purity of 99.8 % (System C). <sup>1</sup>H-NMR (Varian VXR 300, deuterated dimethylsulfoxide, chemical shift in ppm): -CH(CH<sub>3</sub>)- 0.99 (3H, doublet); -CH(CH<sub>3</sub>)- 3.0-3.1 (1H, multiplet); -CH(OH)- 4.60-4.65 (1H, multiplet); -CH<sub>2</sub>-NH- 2.75-2.9 (2H, multiplet); -CH(CH<sub>3</sub>)-CH<sub>2</sub>-2.44-2.5, 2.75-2.9 (2H, two multiplets); -OCH<sub>3</sub> 3.73 (3H, singlet); -CHO 9.61 (1H, doublet); -NH-CHO 8.29 (1H, doublet).; -CH=CH- 6.49 (1H, singlet). In the thermospray mass spectrum the assignment fragments are m/z 345 (MH<sup>+</sup>,

25

30

35

100 %); 327 ( $MH^+ - H_2O$ , 27 %); 166 ( $C_{10}H_{15}N_3O^+$ , 7.2 %), which confirm the structure.

Synthesis of N-[2-(3-formamido-4-hydroxy-phenyl)-2-hydroxy-ethyl]-N,N-dimethyl-N-(p-methoxy- $\alpha$ -methyl-phenylethyl)ammonium fumarate

5 A mixture of formoterol fumarate (500 mg), sodium carbonate (200 mg), methyl iodide (5 ml) and acetonitrile (50 ml) was stirred over night at room temperature. Filtration and evaporation of the filtrate gave an oily solid which was washed with chloroform to give 341 mg (66  
10 %) of the crude N-[2-(3-formamido-4-hydroxy-phenyl)-2-hydroxy-ethyl]-N,N-dimethyl-N-(p-methoxy- $\alpha$ -methyl-phenylethyl)ammonium fumarate. Recrystallization from 95 % ethanol gave a purity of 98.6 % (HPLC system: Licrosphere RP Select B, 5  $\mu$ m, 129x4 mm, 214 nm, gradient elution from  
15 acetonitrile/phosphate buffer (50 mM, pH 3) 16/84 to acetonitrile/phosphate buffer (70/30), 1 ml/ min).  $^1H$ -NMR: -CH(CH<sub>3</sub>)- 1.17 (3H, doublet); N-CH<sub>3</sub> 3.2 (3H, singlet); N-CH<sub>3</sub> 3.3 (3H, singlet); -CH(CH<sub>3</sub>) 4.0 (1H, multiplet); -CH(OH) 5.1-5.2 (1H, broad doublet); -CH(OH) 6.1 (broad  
20 singlet); -OCH<sub>3</sub> 3.76 (3H, singlet); CHO 8.31 (1H, singlet); -NHCHO 9.6 (1H, singlet); -CH=CH- 6.9 (1H, singlet). The electrospray mass spectrum shows the molecular peak at m/z 373 which is in accordance with the proposed structure.

25

The new process according to the invention, which differs from known procedures for the preparation of formoterol fumarate and its derivatives in the following major ways


1. The use of an epoxide as a starting material
- 30 2. Reduction and formylation of the nitro group
3. The optional use of a cosolvent in the separation of the racemates.

The new process is easier to use and gives an end product  
35 with a higher purity than the same compounds prepared according to earlier known processes.

## CLAIMS

1. A process for preparing a compound of the general formula I

5




wherein R<sup>1</sup> is H or a straight or branched alkyl group having 1-5 carbon atoms,

15 A is either  $\begin{array}{c} \text{R} \\ | \\ -\text{N}^+- \\ | \\ \text{R}^2 \end{array}$  wherein R is H or a straight or branched alkyl group having 1-5 carbon atoms and R<sup>2</sup> is H or a straight or branched alkyl group having

20 1-5 carbon atoms; or  $\begin{array}{c} \text{R} \\ | \\ -\text{N}- \end{array}$  wherein R is as defined above,

or a pharmaceutically acceptable fumarate and/or solvate thereof, in the form of the pure racemates or the mixture of the four isomers, by

25 a) reacting




35

II

III

16

to give compound IV




IV

10

b) reducing and formylating compound IV to give compound V

15



V

25

c) forming the fumarate of compound V and resolving the racemates by crystallization,

d) extracting the base of the desired racemate of compound V,

e) hydrogenolyzing of the protecting benzyl groups of said base of compound V to obtain compound I wherein A is  $\begin{matrix} \text{H} \\ | \\ -\text{N}- \end{matrix}$  and R<sup>1</sup> is H, and optionally

f) forming a fumarate and/or solvate of compound I, and optionally

g) when

5 A is either  $\begin{array}{c} \text{R} \\ | \\ -\text{N}^+- \\ | \\ \text{R}^2 \end{array}$  wherein R is H or a straight or branched alkyl group having 1-5 carbon atoms and R<sup>2</sup> is H or a straight or branched alkyl group having

10  $\begin{array}{c} \text{R} \\ | \\ -\text{N}- \end{array}$  wherein R is a straight or branched alkyl group having 1-5 carbon atoms, and R<sup>1</sup> is as defined above, alkylating the compound obtained in step e) or f).

15 2. A process according to claim 1, characterized in that step a) is carried out in the presence of a solvent, such as lower alcohols, at reflux temperatures or in the absence of a solvent at temperatures preferably at 80-120°C .

20 3. A process according to any one of claims 1-2, characterized in that step b) is a one step reaction with Raney-nickel/formic acid or a two step reaction comprising catalytic reduction of the nitro group followed by formylation in excess of formic acid.

25 4. A process according to any one of claims 1-3, characterized in that the resolving of the racemates by crystallization in step c) is carried out in a solvent system comprising ethyl acetate, isopropyl acetate and/or  
30 methyl isobutylketone.

5. A process according to claim 4, characterized in that the solvent system further comprises small amounts of solvents more polar than the solvents defined in claim 4,  
35 such as dimethylformamide, dimethylsulfoxide and/or methanol.


18

6. A process according to claim 5, characterized in that the amount of the more polar solvent preferably is less than 15 %.

5 7. A process according to any one of claims 1-6, characterized in that R is hydrogen and R<sup>1</sup> is hydrogen.

8. A process according to any one of claims 1-6, characterized in that R and/or R<sup>2</sup> are straight or branched  
10 alkyl groups having 1-5 carbon atoms.

9. A compound of the general formula I



wherein R<sup>1</sup> is H or a straight or branched alkyl group having 1-5 carbon atoms,

25 A is either  $\begin{array}{c} \text{R} \\ | \\ -\text{N}^+- \\ | \\ \text{R}^2 \end{array}$  wherein R is a straight or branched alkyl group having 1-5 carbon atoms and R<sup>2</sup> is H or a straight or branched alkyl group having

30 1-5 carbon atoms; or  $\begin{array}{c} \text{R} \\ | \\ -\text{N}- \end{array}$  wherein R is as defined above,

or a pharmaceutically acceptable fumarate and/or solvate thereof, in the form of the pure racemates or the mixture of the four isomers.

35

# INTERNATIONAL SEARCH REPORT

International Application No PCT/SE 91/00643

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup> According to International Patent Classification (IPC) or to both National Classification and IPC IPC5: C 07 C 231/14, 231/10, 233/43		
<b>II. FIELDS SEARCHED</b> Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
IPC5	C 07 C	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched <sup>8</sup>		
SE,DK,FI,NO classes as above		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>		
Category *	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
A	US, A, 3933911 (BRIAN GEOFFREY MAIN) 20 January 1976, see the whole document --	1-8
A	Chemical Abstracts, volume 112, no. 19, 7 May 1990, (Columbus, Ohio, US), see, abstract 178373t, & ES, A, 2005492 (Preparation of N- <u>2</u> -hydroxy-5- <u>1</u> -hydroxy-2- <u>2</u> -(4-methoxyphenyl) -1-methylethylaminoethylphenylformamide, i.e. formoterol) --	1-9
A	DE, C2, 2366625 (YAMANOUCHI PHARMACEUTICAL CO., LTD.) 16 August 1973, see the claims -- -----	9
<p>* Special categories of cited documents:<sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
18th December 1991		1991 -12- 9
International Searching Authority		Signature of Authorized Officer
SWEDISH PATENT OFFICE		Solveig Gustavsson Solveig Gustavsson

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO. PCT/SE 91/00643**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the Swedish Patent Office EDP file on 31/10/91. The Swedish Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A- 3933911	76-01-20	AU-D- 7120574	76-01-15
		BE-A- 817826	75-01-20
		CA-A- 1043349	78-11-28
		CH-A- 612915	79-08-31
		DE-A-C- 2434911	75-02-06
		FR-A-B- 2237624	75-02-14
		GB-A- 1468156	77-03-23
		JP-C- 1250574	85-02-14
		JP-A- 50047936	75-04-28
		JP-B- 59022696	84-05-28
		LU-A- 70551	74-11-28
		NL-A- 7409453	75-01-21
		SE-B-C- 417197	81-03-02
		SE-A- 7409387	75-01-20
		US-A- 3957870	76-05-18
		US-A- 4041074	77-08-09
DE-C2- 2366625	73-08-16	DE-A-C- 2305092	73-08-16
		FR-A-B- 2173993	73-10-12
		GB-A- 1415256	75-11-26
		JP-C- 1110414	82-08-31
		JP-A- 48080528	73-10-29
		JP-B- 56053537	81-12-19
		US-A- 3994974	76-11-30
		JP-A- 49000237	74-01-05
		JP-A- 49005934	74-01-19